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the validated source model. The MC simulations were done using the 
original treatment parameters; source strength, dwell positions and 
times. The MC dose metrics for PTV and skin D90 and D0.1cc were 
compared to the TG-43 treatment plan. 
Results: A validation simulation using a water-based geometry agreed 
to within 1% of the treatment plan's D90. The patient dose was scored 
in terms of dose to water in medium (Dw,m) and compared against the 
TG-43 plan (Dw,w) (figure). All dose metrics demonstrate a decrease in 
Dw,m compared to Dw,w on the order of 10-30%. The TG-43 D90 is 
reduced by 20% in Dw,m. The D0.1cc for the skin showed a 30% reduction 
when recalculated in MC. The reduction is the result of a complex 
combination of factors such as tissue heterogeneity, loss of 
backscatter at the skin/lung interface and the applicator design, in 
particular the wall of the balloon applicator which reduces the dose 
fluence by approximately 7% due to the presence of barium sulfate (a 
high-Z compound).  
 
  
Figure: Top Right: Isodose comparison of MC-based(solid lines) versus 
TG-43-based dosimetry (dashed lines) Bottom: Ratio of Dw,w to Dw,m. 
Black lines denotes PTV. Dw,m to air/lung is reported as zero. Top left: 
HU-based tissue segmentation of the breast. 
 
Conclusions: Results indicate that effects of under-dosing on the dose 
distribution for Dw,m compared to Dw,w. This study demonstrates the 
need for more comprehensive dosimetry model to the current TG-43 
dose formulation.  
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Purpose/Objective: Model based dose calculation algorithms 
(MBDCAs), recently introduced in treatment planning systems for 
brachytherapy (BT), calculate absorbed doses to the medium (i.e. to 
the tissues). The aim of this work was to shed light on the yet 
unresolved issue of which method for converting absorbed dose to 
medium Dm,m into absorbed dose to water Dw,m is most suitable for BT. 
'Small cavity theory' implies conversion by stopping power ratios and is 
applicable when ranges of secondary electrons are long compared to 
cavity dimensions while 'large cavity theory' implies conversion by 
ratios of mass energy absorption coefficients and is applicable when 
ranges are short in relation to cavity dimensions. The relationship 
between cavity size and applicable cavity theory at the photon 
energies of interest to BT, i.e., in the energy range 20-1000 keV, was 
investigated. An argument in favor of reporting Dw,m has been that 
there exists a radiotherapy target being of cellular dimensions that is 
more water-like in all tissues than the average bulk medium obtained 
from CT images and used in MBDCA calculations. 
Materials and Methods: Burlin cavity theory was applied to estimate 
photon energies at which cavity sizes in the range 1 nm -10 mm can 
be considered small or large. Photon- and electron energy spectra 
were calculated at 1 cm distance from the central axis in phantoms of 
bone, muscle and adipose tissue for centrally placed 20, 50, 300 keV, 
125I, 169Yb and 192Ir photon point sources; ratios of mass collision-
stopping powers and mass energy absorption coefficients were 
calculated as applicable to convert Dmed into Dw,med for small and large 
cavities.  
Results: The figure shows the parameter d in the Burlin theory as 
function of photon energy and cavity size; a cavity is small when d is 
close to unity and large when d is close to zero.  
1-10 nm sized cavities are small at all investigated photon energies; 
100 μm cavities are large only at photon energies < 20 keV and 
cavities of mm dimensions are required for large cavity theory to be 
suitable at 192Ir photon energies around 300 keV.  
 Conclusions: The question whether to report Dm,m or Dw,m arises when 
using MBDCAs for BT similar to in external beam therapy. However in 
BT the additional problem of deciding appropriate cavity dimensions 
arises due to the short ranges of secondary electrons. Free radicals 
from DNA bound water of nm dimensions contribute to complex DNA 
damage and cell killing and may be the most important water 
compartment in cells which would imply use of ratios of mass-collision 
stopping-powers for converting Dm into Dw,m in BT as used in external 
beam therapy. Stopping power ratios vary little with energy and lead 
to numerical values for Dw,m/Dm,m similar to those reported for other 
radiotherapy modalities. Mass energy absorption coefficient ratios 
imply large differences in Dm /Dw,m over the BT energy range and to 
those obtained in external beam therapy. 
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Purpose/Objective: To analyse late urogenital (UG), gastrointestinal 
(GI) and vaginal (VG) morbidity in patients treated for cervical cancer 
by IGABT in a multicentre setting. 
Materials and Methods: RetroEMBRACE is a retrospective collection of 
data from patients treated for cervical cancer by IGABT using the 
GEC-ESTRO guidelines. At present, 796 patients have been registered 
from 12 institutions. Detailed data on morbidity grade 1-5 (CTCAE, 
V3.0) has been entered in 533 patients from 5 institutions. In these 
patients, FIGO-stage was IB1-IIA/IIB/IIIA-IVAB in 28%/48%/24%. Eighty-
four percent were squamous cell carcinomas. In all patients IGABT 
was preceded by 3D conformal radiotherapy or Intensity Modulated 
Radiotherapy with mean dose of 46 ±3 Gy in 26 ±2 fractions and 
weekly concomitant cisplatinum in 76%. A nodal boost of 57 ±3 Gy was 
given to 16% and a parametrial boost of 55 ±2 Gy was given to 4%. 
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IGABT was based on MRI in 82% of the patients. Sixty percent were 
treated with high dose rate and the remaining 40% had pulsed dose 
rate BT. Eighty-four percent of the patients were treated with 
intracavitary (IC) technique. In the remaining 16% a combined IC and 
interstitial applicator was used.  
Results: Total prescribed mean dose for HR-CTV (D90) was 89 ±15 Gy, 
D2cc was 89 ±12 Gy for bladder, 64 ±8 Gy for rectum and 65 ±10 Gy for 
sigmoid. At a median follow-up of 31 (3-150) months, two patients had 
died due to morbidity (one fistula and one vaginal bleeding). No other 
G5 events were diagnosed. Actuarial morbidity G3-G5 at 5-years was 
4% for UG tract, 6% for GI tract and 4% for VG. Actuarial morbidity G2-
G5 at 5-years was 19% for UG tract, 18% for GI tract and 22% for VG.  
Conclusions: In this retrospective multicentre study 3D conformal RT 
± cisplatinum and IGABT compares favourble with previous studies on 
morbidity after 2D BT. These findings illustrate that the GEC-ESTRO 
guidelines work in a multicentre setting and serve as benchmark for 
future studies on IGABT for cervical cancer. 
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Purpose/Objective: To give a first interim report on prospectively 
assessed vaginal morbidity in the ongoing EMBRACE study (European 
and International study on MRI-guided brachytherapy in locally ad-
vanced cervical cancer, www.embracestudy.dk) and to describe a 
dose response relationship. Currently, no dose response relationship 
for vaginal morbidity has been established.  
Materials and Methods: Patients with locally advanced cervical 
cancer who underwent combined external beam radiotherapy ± 
chemotherapy and MRI-guided brachytherapy following the GEC-ESTRO 
guidelines were included. Vaginal morbidity was prospectively as-
sessed with CTCAE v.3 at baseline and every 3 months after end of 
treatment for the first 2 years. The assessment included vaginal 
dryness, mucositis, bleeding, stenosis, fistula and any other vaginal 
symptoms (reported in free text field). The dose to the ICRU rectal 
point was used as a surrogate for intermediate to high dose to the 
upper vagina in order to establish a dose effect relationship for vagin-
al morbidity with binary logistic regression analysis (dose response 
curves). 
Results: Information on vaginal morbidity was available in 523 pa-
tients from 19 centers for analysis. Median follow-up was 14 months 
(286 patients with one year and 108 patients with 2 year follow-up). 
Crude incidences of individual vaginal symptoms are shown in table 1; 
no G5 morbidity occurred.  
 Most frequent other vaginal symptoms were adhesions. Actuarial 
analyses resulted in 78% probability of any vaginal morbidity G≥1 and 
19% G≥2 after 1 year, and 92% and 34% after 2 years. In 468 patients, 
information on vaginal morbidity and dose to the ICRU rectal point 
was available. In univariate logistic regression analysis, dose to the 
ICRU rectal point was associated with higher frequency of G≥2 vaginal   
morbidity (p= 0.002, figure 1).   
    
  
 
Conclusions: Severe vaginal morbidity (G3/G4) is rare in the first two 
years after definitive radiochemotherapy including MRI-guided adap-
tive brachytherapy. However, the probability for milder to moderate 
morbidity (G1/G2) is high in the first year (78%) and further increases 
in the second year (92%). The ICRU rectal point dose correlates signif-
icantly with occurrence of G2≥2 vaginal morbidity. Further investiga-
tions with longer follow-up, including the relevance of confounding 
factors, are required. Additionally, analyses of individual vaginal 
endpoints and further dose parameters at the lower and middle 
vagina, especially also sensitive to external beam, are planned and 
will allow in future more detailed conclusions.  
 
OC-0088   
Salvage Re-irradiation using high dose rate brachytherapy in 
recurrent carcinoma of uterine cervix 
N. Kalyani1, U. Mahantshetty1, R. Engineer1, S. Chopra1, S.V. 
Jamema2, Y. Ghadi2, D.D. Deshpande2, S.K. Shrivastava1 
1TATA Memorial Hospital, Radiation Oncology, Mumbai, India  
2TATA Memorial Hospital, Medical Physics, Mumbai, India  
 
Purpose/Objective: The purpose of this study was to determine 
feasibility of salvage re-irradiation with high dose rate (HDR) 
brachytherapy and patterns of failures in previously irradiated 
patients diagnosed with recurrent carcinoma of the uterine cervix. 
Materials and Methods: Twenty-eight previously irradiated patients 
presenting with central recurrence with / without early parametrial 
disease and deemed not suitable for exenteration surgery by Gynec 
oncologist, were treated with salvage re-irradiation using HDR 
brachytherapy at our institute. All these patients underwent imaging 
(CT / MR/ PET-CT) to rule out metastatic disease elsewhere in the 
body. Martinez Universal Perineal Interstitial Template (MUPIT) was 
used in 24 patients while Vienna applicator in 4 patients. Median age 
for the cohort was 54 years (range 38-73 years). Median interval 
between two radiation schedules was 25 months (inter-quartile range 
13-49 months). Median delivered dose was 40.3 Gy EQD2 (inter-
quartile range 36.9 - 46.6 Gy). None of the patients received any form 
of Chemotherapy (concomitant / adjuvant /salvage). 
Results: All patients tolerated salvage re-irradiation with HDR 
brachytherapy well. None of the patients reported any significant 
acute toxicity. The median follow up for whole group was 16 months 
(inter-quartile range 7-20 months). Complete response was seen in 21 
patients, partial response in 6 patients and progressive disease in one 
patient on clinic-radiological assessment. At last follow up 15 patients 
were alive, of which 13 were diseases free. Ten patients developed 
central recurrence (biopsy proven), 3 patients had loco-regional 
recurrence while 2 patients had distant metastases. Overall, 
13/28patients developed local recurrence. The local recurrence rate 
was higher inpatients receiving doses less than 40 Gy EQD2.The 
median disease free survival(DFS) and overall survival (OS) was 16 and 
20 months respectively. Two year DFS and OS were 33% and 44% 
respectively. Median DFS was more for patients with more than 25 
month interval between two RT schedules, while tumour size and RT 
dose had no impact on overall DFS. Two patients developed grade III 
radiation proctitis, 3 patients had grade II radiation cystitis and 2 
patients developed grade II bowel complications after re-irradiation. 
One patient required hyperbaric oxygen therapy for chronic non-
healing ulcer at vagina.  
Conclusions: Salvage re-irradiation using HDR brachytherapy is 
feasible in select group of patients with central recurrence. The 
